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Reply
We thank the Editor for allowing us to answer Mr Colone’s
letter commenting on our recently published article, and therefore
better explain some of the reasons for our disappointment with our
thankfully limited experience with the Endofit graft (Endomed,
Phoenix, Ariz). We were not surprised that a member of the
company stood up to defend its corporate interests. It was the
president himself that did so. However, he must have been widely
misled since his letter contains several significantly untrue and
imprecise statements.
First of all, this letter depicts us as amateurs. We would like to
point out that aortic pathology is not alien to our center. To date,
we have treated 438 patients with descending thoracic and thora-
coabdominal aortic disease and 3167 with abdominal aortic dis-
ease. We have been familiar with endovascular techniques in dif-
ferent districts1 for many years. Our experience with the
endovascular treatment of abdominal aortic aneurysm goes back to
1998,2 and we have implanted more than 150 abdominal en-
dografts. We implanted our first thoracic endograft in June 1999,
and by the time we used the first Endofit device, we had implanted
Gore Excluder TAG thoracic grafts in 29 patients and Talent
thoracic grafts in 2 patients with no perioperative mortality or
major morbidity. Had Mr. Colone read the 11th paragraph of the
Discussion section of our article, he might have avoided his com-
ments on our learning curve. Interestingly, after we abandoned
Endofit grafts, we treated 28 additional cases of arch and descend-
ing thoracic aorta disease, employing different endografts, with no
casualty or permanent neurologic deficit, including 2 cases of total
arch replacement (a case report of which has been accepted for
publication in the Texas Heart Institute Journal) and 1 case of
treatment of thoracoabdominal aortic aneurysm.3
Anyway, a more experienced surgeon who could have served
as a proctor during the first implants would have been extremely
welcome at our center. Regrettably, this service was never offered
to us. On the contrary, after the first few implants, Dr Melissano
himself was asked to serve as proctor for the first implant of a
thoracic Endofit graft at a different institution.
The only assistance that was provided to us was offered by a
“Product Specialist,” a representative of the Italian distributor
Serom Medical Technology srl. During the first implant, following
our question regarding the possibility of having a graft custom
made without the proximal bare stent in order to avoid interfer-
ence with the innominate artery or left common carotid artery, he
answered that a custom-made device was not needed since, simply
by loading the graft upside down in the introducer, the bare stent
would land in the distal thoracic aorta. He assured us that this
procedure had been done before and was absolutely safe. This
obviously turned out not to be the case.
Preoperative computed tomography (CT) scans were ob-
tained for all the patients. CT scans were also obtained for all but 1
of the survivors postoperatively, as stated in the article. All grafts
were chosen on the basis of the CT scans, with the recommended
oversizing. Regrettably, this was not stated in the article; we
apologize to the readers and we are thankful to the Editor for the
opportunity to state this now. Therefore, undersizing is not the
most likely cause of the endoleaks that we observed. A different
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mechanism is suggested in the 7th paragraph of the Results section
and in Figs 5 and 6. The readers may judge for themselves.
When the Figure that accompanies this letter is examined, the
stent fractures and the collapsed graft are findings that are too
obvious to require any further comment. Whether the reason was
material fatigue, mechanical strain during deployment, or perhaps
other problems during the assembly of the stent graft and its
loading into the cartridge is beyond our field of knowledge.
It must be definitely noted that we never received any request
for the surgical records for each reported incident. On the con-
trary, the company, which was informed in a timely manner by us
about the mishaps and received the defective material, never an-
swered with a written statement or comment but only verbally
stated their regrets.
Unfortunately, the paper by Ramaiah et al4 appeared in the
2003 Sep-Oct issue of the Journal of Cardiac Surgery and was
therefore not available to us at the time our article was written.
These authors report 37 patients who underwent endovascular
stent-graft repair of the thoracic aorta for various disease entities,
using a customized thoracic graft (Endomed). Among them: ”One
patient died in the operating room from iliac rupture and one died
from embolization/stroke in the immediate postoperative period.
Two patients died within 30 days from comorbid factors.” We
would have certainly included this article in our discussion if we
had had the opportunity.
We indeed agree that thoracic endografting carries a risk for
neurologic complications related to intraluminal manipulations
and large introducer sheaths, and we never claimed that this risk is
singular to the Endofit grafts. However, as we mentioned in the
Material and Methods section, once this graft was loaded into the
introducer sheath, the introducer-graft system no longer had a
tapered tip and, being sharp-edged, could not be safely advanced
into the aorta; adjustments could only be made backwards. If the
graft needed to be repositioned forward, the procedure had to be
restarted.
We are certainly surprised that Mr Colone criticizes a statistical
comparison between different endografts, since we never at-
tempted to do so in our article.
Although we commend Mr. Colone’s company for modifying
their product with regard to flexibility, strength, and delivery
system, he must be aware that, alas, the problems that emerged
with first-generation Endofit devices were not unique to our
experience. In fact, we had several personal communications from
colleagues reporting severe problems. Moreover, in the United
Kingdom, the Medical Devices Agency (an executive agency of the
Department of Health, UK) on Feb 20, 2003, issued a “Medical
Device Alert” concerning several fatal and non-fatal problems with
this graft. The alert may be found at the following link: http://
www.medical-devices.gov.uk/mda/mdawebsitev2.nsf/0/f13720
57cca7855480256cd40041d48a
As a final remark, we would like to note that European
regulations are less restrictive than US Food and Drug Adminis-
tration regulations. In the past, these less restrictive regulations
have sometimes permitted European physicians to use excellent
drugs and medical devices years before their American peers were
allowed to do so. However, this experience reminded us once again
how that there is always another side to the coin.
Germano Melissano, MD
Roberto Chiesa, MD
Vita-Salute University
Scientific Institute H. San Raffaele
Milano, Italy
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